On July 27, Empower Founder and CEO Shaun Noorian joins Second Opinion Media for a live panel with voices from pharmacy, obesity medicine, and urology on where the science and regulation are moving, what patients should know before starting treatment, and where access and innovation are likely to intersect next
Generally, improvements in symptoms can be observed within a few days of administration
Patients should understand that if they are obtaining BPC-157, it is not coming from a vetted, FDA-inspected source
In a trial of patients with T2DM and BMI 27 kg/m2 or more receiving semaglutide injection for weight management, retinal disorders were reported by 6.9% of patients treated with semaglutide 2.4 mg/week, 6.2% of patients treated with semaglutide 1 mg/week, and 4.2% of patients treated with placebo